Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/42918
Title: | Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients | Authors: | Van Meerhaeghe, Tess Murakami, Naoka Le Moine, Alain Brouard, Sophie SPRANGERS, Ben Degauque, Nicolas |
Issue Date: | 2024 | Publisher: | OXFORD UNIV PRESS | Source: | Clinical Kidney Journal, 17 (4) (Art N° sfae061) | Abstract: | Cancer is a common complication after kidney transplantation. Kidney transplant recipients (KTR) have a 2- to 4-fold higher risk of developing cancer compared to the general population and post-transplant malignancy is the third most common cause of death in KTR. Moreover, it is well known that certain cancer types are overrepresented after transplantation, especially non-melanoma skin cancer. Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer, with remarkable survival benefit in a subgroup of patients. ICI are monoclonal antibodies that block the binding of specific co-inhibitory signaling molecules. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand programmed cell death ligand 1 (PD-L1) are the main targets of ICI. Solid organ transplant recipients (SOTR) have been excluded from clinical trials owing to concerns about tumor response, allo-immunity, and risk of transplant rejection. Indeed, graft rejection has been estimated as high as 48% and represents an emerging problem. The underlying mechanisms of organ rejection in the context of treatment with ICI are poorly understood. The search for restricted antitumoral responses without graft rejection is of paramount importance. This review summarizes the current knowledge of the use of ICI in KTR, the potential mechanisms involved in kidney graft rejection during ICI treatment, potential biomarkers of rejection, and how to deal with rejection in clinical practice. | Notes: | Sprangers, B (corresponding author), UHasselt, Biomed Res Inst, Dept Immunol & Infect, Diepenbeek, Belgium.; Sprangers, B (corresponding author), Ziekenhuis Oost Limburg, Dept Nephrol, Genk, Belgium. ben.sprangers@zol.be |
Keywords: | allograft rejection;cancer;immune checkpoint inhibitors;kidney transplantation | Document URI: | http://hdl.handle.net/1942/42918 | ISSN: | 2048-8505 | e-ISSN: | 2048-8513 | DOI: | 10.1093/ckj/sfae061 | ISI #: | 001199710700001 | Rights: | The Author(s) 2024. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fine-tuning tumor- and allo-immunity_ advances in the use of immune checkpoint inhibitors in kidney transplant recipients.pdf | Published version | 714.21 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.